Effect of various absorption enhancers based on tight junctions on the intestinal absorption of forsythoside A in Shuang-Huang-Lian, application to its antivirus activity

Pharmacognosy Magazine

Volumn 10, Issue 37, 2014, Pages 9-17

  Zhou, Wei ^a,b,c   Zhu, Xuan ^d   Yin, Ai ^a   Cai, Bao ^a   Wang, Hai ^d   Di, Liuqing ^a,b,c   Shan, Jin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jiangsu Provincial TCM High Efficient Drug Delivery System Engineering Technology Research Center   (China)

^c Nanjing Engineering Research Center for Industrialization of Chinese Medicine Pellets   (China)

^d AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Absorption enhancers; antivirus activity; Forsythoside A; Shuang Huang Lian; tight junction

Indexed keywords

EID: 84894222932     PISSN: 09731296     EISSN: 09764062     Source Type: Journal    
DOI: 10.4103/0973-1296.126651     Document Type: Article

References (26)

1. Lv M. B. Progresses in the clinical application of Shuang-Huang-Lian preparations. Chin J Hosp Pharm 1997;17:81-2.
2. Hua J, Ye M, Guo H, Yang M, Wang BR, Guo DA. Analysis of multiple constituents in a Chinese herbal preparation Shuang-Huang-Lian oral liquid by HPLC-DAD-ESI-MSn. J Pharm Biomed Anal 2007;28:430-8.
3. Chinese Pharmacopoeia Commission, 2010. The Pharmacopoeia of the People's Republic of China Version (2010). Beijing: Chinese Medical Science Technology Press; 2010. 611 pp.
4. Diaz Lanza AM, Abad Martinez MJ, Fernandez Matellano L, Recuero Carretero C, Villaescusa Castillo L, Silvan Sen AM, et al. Lignan and phenylpropanoid glycosides from Phillyrea latifolia and their in vitro anti-inflammatory activity. Planta Med 2001;67:219-23.
5. Shi Y, Shi RB, Liu B, Lu YR, Du LJ. Isolation and elucidation of chemical constituents with antiviral action from yinqiaosan on influenza virus. Zhongguo Zhong Yao Za Zhi 2003;28:43-7.
6. Zhao Y, Li F, Yang J, An X, Zhou M. Effect of phillyrin on the anti-obesity in nutritive obesity mice. Zhong Yao Cai 2005;28:123-4.
7. Li YX, Peng C, Ye LH, Zhang RQ, Jiang XH. Investigation on the absorption of phillyrin and forsythiaside in rat digestive tract. Eur J Drug Metab Pharmacokinet 2011;36:79-85.
8. Wang L, Wang ZJ, Wo SK, Lau CB, Chen X, Huang M, et al. A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to Si Wu Tang. Int J Pharm 2011;406:99-105.
9. Zhang LW, Zhao CG, Yang P. Study on the antioxidant activity and structure-activity relationship of Forsythiaside. Chin Pharm J 2003;38:334-6.
10. Qu H, Zhang Y, Wang Y, Li B, Sun W. Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspense. J Pharm Pharmacol 2008;60:261-7.
11. Ma YY, Zhang ZW, Li HW, Sun JH, Xu CY, Wu GJ. Effects of forsythoside A on the Expression of IFN-α and Mx1. Sci Agr Sin 2010;43:3237-43.
12. Ye JX, Wei W, Quan LH, Liu CY, Chang Q, Liao YH. An LC. MS/MS method for the simultaneous determination of chlorogenic acid, forsythiaside A and baicalin in rat plasma and its application to pharmacokinetic study of Shuang-huang-lian in rats. J Pharm Biomed Anal 2010;52:625-30.
13. Tian L, Zhou W, Di LQ, Yu JH, Dan JJ, Bi XL, et al. Study on in vitro antibacterial effects correlation between the main active components in Shuang-Huang-Lian oral liquid. J Nanjing Univ Tradit Chin Med 2012;28:89-91.
14. Zhou W, Di LQ, Wang J, Shan JJ, Liu SJ, Ju WZ, et al. Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models. Acta Pharmacol Sin 2012;33:1069-79.
15. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther 1998;284:362-9.
16. Bernkop-Schnurch A. Chitosan and its derivatives: Potential excipients for peroral peptide delivery systems. Int J Pharm 2000;194:1-13.
17. Gao Y, He L, Katsumi H, Sakane T, Fuiita T, Yamamoto A. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int J Pharm 2008;359:70-8.
18. Zhou W, Di LQ, Bi XL, Zhao XL. Determination of baicalin, chlorogenic acid, forsythin and forsythoside A in Shuang-Huang-Lian oral liquid by dual-wavelength HPLC. Chin J Tradit Chin Med Pharm 2011;26:2111-3.
19. Jin X, Zhang ZH, Sun E, Tan XB, Zhu FX, Li SL, et al. Preparation of icariside α - phospholipids complex and its absorption across Caco-2 cell monolayers. Pharmazie 2012;67:293-8.
20. Mehrbod P, Motamed N, Tabatabaian M, Soleimani ER, Amini E, Shahidi M, et al. In vitro antiviral effect of "Nanosilver" on influenza virus. Drug 2009;17:88-93.
21. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9.
22. Li YH, Zhang M, Wang JC, Zhang S, Liu JR, Zhang Q. Effects of absorption enhancers on intestinal absorption of lumbrokinase. Yao Xue Xue Bao 2006;41:939-44.
23. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reacher therapeutic levels. J Drug Target 2005;13:573-83.
24. Thanou M, Nihot MT, Jansen M, Verhoef JC, Junginger HE. Mono-N-Carboxymethyl Chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci 2001;90:38-46.
25. Thanou M, Henderson S, Kydonieus A, Elson C. N-sulfonato-N, O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecular. J Control Release 2007;117:171-8.
26. Konishi Y, Kobayashi S. Transepithelial transport of chlorohenic acid, caffeic acid, and their colonic metabolites in intestinal Caco-2 cell monolayers. J Agric Food Chem 2004;52:2518-26.